Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.
Sera from 20 myeloma patients and 12 normal controls were analysed for the presence of syndecan-1 and matrix metalloproteinase-9 (MMP-9). The level of syndecan-1 in the serum was elevated in 7/20 (3 5%) myeloma patients whilst 6/19 patients (31%) had decreased serum MMP-9 activity. The presence of increased syndecan-1 was associated with decreased serum MMP-9. Both elevated syndecan-1 and decreased MMP-9 were associated with higher marrow plasmacytosis, serum beta-2 microglobulin and paraprotein levels. These data provide evidence that the syndecan-1 ectodomain is shed in vivo. Quantitation of serum syndecan-1 may be a useful measure of tumour mass and may have important implications for myeloma biology.
Dhodapkar
M V
MV
Division of Hematology-Oncology, University of Arkansas for Medical Sciences and VA Medical Center, Little Rock, USA.
Kelly
T
T
Theus
A
A
Athota
A B
AB
Barlogie
B
B
Sanderson
R D
RD
D000328:Adult; D000368:Aged; D015153:Blotting, Western; D005260:Female; D006801:Humans; D015151:Immunoblotting; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008666:Metalloendopeptidases / Q000097:blood*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000201:enzymology; D011509:Proteoglycans / Q000097:blood*; D053668:Syndecan-1; D053667:Syndecans; D001613:beta 2-Microglobulin / Q000378:metabolism
D008562:Membrane Glycoproteins; D011509:Proteoglycans; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans; D001613:beta 2-Microglobulin; D008666:Metalloendopeptidases